Effect of omega-3 supplementation on cardiometabolic indices in diabetic patients with non-alcoholic fatty liver disease: a randomized controlled trial

Table 3 Effect of omega-3 on cardiometabolic indices in diabetic patients with NAFLD

Indices	Omega-3 (n = 30)	Placebo (n = 30)	P^†	P^††
AIP				0.13
Baseline	0.49 ± 0.22	0.44 ± 0.19	0.36
Week 12	0.38 ± 0.28	0.41 ± 0.27	0.67
P	0.007	0.33
Mean change	−0.11 ± 0.20	−0.03 ± 0.16	0.10
Castelli risk index I				0.46
Baseline	3.63 ± 0.9	3.41 ± 0.7	0.31
Week 12	3.38 ± 0.9	3.34 ± 0.7	0.88
P	0.05	0.62
Mean change	−0.25 ± 0.6	−0.07 ± 0.7	0.29
Castelli risk index II				0.70
Baseline	2.11 ± 0.6	1.97 ± 0.5	0.55
Week 12	1.87 ± 0.6	1.83 ± 0.5	0.81
P	0.01	0.15
Mean change	−0.24 ± 0.5	−0.14 ± 0.5	0.47
AC				0.40
Baseline	2.63 ± 0.9	2.41 ± 0.7	0.31
Week 12	2.38 ± 0.9	2.34 ± 0.7	0.88
P	0.05	0.62
Mean change	−0.25 ± 0.6	−0.07 ± 0.7	0.29

P values are computed by independent t-test and data are expressed as mean ± standard deviation (SD)
P: resulted from comparisons within groups by paired t-test
P^†: resulted from comparisons between two groups by independent t-test
P^††: resulted from comparing the mean change from baseline between groups using univariate ANCOVA after adjusting for energy intake and weight change
NAFLD Non-alcoholic fatty liver disease, AIP Atherogenic index of plasma, AC Atherogenic coefficient

ISSN: 2055-0928